Biomarker-based precision dose finding for immunotherapy combined with radiotherapy

DOI10.1002/BIMJ.202200246zbMATH Open1541.62307MaRDI QIDQ6572286FDOQ6572286

Authors: Yan Han, Rui Zhang, Beibei Guo 

Publication date: 15 July 2024

Published in: Biometrical Journal (Search for Journal in Brave)

zbMATH Keywords

radiotherapyimmunotherapybiomarkersdose findingBayesian adaptive designpatient subgroupsimmunoRTPD-L1 expression

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Sampling-Based Approaches to Calculating Marginal Densities
• Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• A weakly informative default prior distribution for logistic and other regression models
• The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Robust EM continual reassessment method in oncology dose finding
• A Bayesian phase I/II trial design for immunotherapy
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
• Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups
• gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points
• Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times

This page was built for publication: Biomarker-based precision dose finding for immunotherapy combined with radiotherapy

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6572286)